The CARA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CARA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CARA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CARA Detailed Price Forecast - CNN Money||View CARA Detailed Summary - Google Finance|
|View CARA Detailed Summary - Yahoo! Finance||View CARA Stock Research & Analysis - Zacks.com|
|View CARA Trends & Analysis - Trade-Ideas||View CARA Major Holders - Barrons|
|View CARA Call Transcripts - NASDAQ||View CARA Breaking News & Analysis - Seeking Alpha|
|View CARA Annual Report - CompanySpotlight.com||View CARA OTC Short Report - OTCShortReport.com|
|View CARA Fundamentals - TradeKing||View CARA SEC Filings - Bar Chart|
|View Historical Prices for CARA - The WSJ||View Performance/Total Return for CARA - Morningstar|
|View the Analyst Estimates for CARA - MarketWatch||View the Earnings History for CARA - CNBC|
|View the CARA Earnings - StockMarketWatch||View CARA Buy or Sell Recommendations - MacroAxis|
|View the CARA Bullish Patterns - American Bulls||View CARA Short Pain Metrics - ShortPainBot.com|
|View CARA Stock Mentions - StockTwits||View CARA Stock Mentions - PennyStockTweets|
|View CARA Stock Mentions - Twitter||View CARA Investment Forum News - Investor Hub|
|View CARA Stock Mentions - Yahoo! Message Board||View CARA Stock Mentions - Seeking Alpha|
|View Insider Transactions for CARA - SECform4.com||View Insider Transactions for CARA - Insider Cow|
|View CARA Major Holdings Summary - CNBC||View Insider Disclosure for CARA - OTC Markets|
|View Insider Transactions for CARA - Yahoo! Finance||View Institutional Holdings for CARA - NASDAQ|
|View CARA Stock Insight & Charts - FinViz.com||View CARA Investment Charts - StockCharts.com|
|View CARA Stock Overview & Charts - BarChart||View CARA User Generated Charts - Trading View|
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
Posted on Friday June 11, 2021
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned subsidiary, Enteris BioPharma, received a $10 million milestone payment from Cara Therapeutics (Nasdaq: CARA) related to the license agreement for the Peptelligence® oral formulation technology utilized in Oral KORSUVA™, the oral formulation of Cara's first-in-class KOR agonist, CR845/difelikefalin. Enteris i
Could The Cara Therapeutics, Inc. (NASDAQ:CARA) Ownership Structure Tell Us Something Useful?
Posted on Wednesday June 09, 2021
A look at the shareholders of Cara Therapeutics, Inc. ( NASDAQ:CARA ) can tell us which group is most powerful...
Is Cara Therapeutics a Buy for Summer 2021?
Posted on Saturday May 29, 2021
The future of this troubled clinical-stage biotech rests on a single drug candidate that management hopes will treat an extremely common condition.
Cara Therapeutics to Present at the Jefferies Healthcare Conference
Posted on Tuesday May 25, 2021
STAMFORD, Conn., May 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 11:00 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system and on immune cells. In the Company’s KALM™-1 and KALM-2 Phase 3 trials and two Phase 2 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe CKD-aP. The FDA has accepted and granted Priority Review for the NDA for KORSUVA (difelikefalin) Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in PBC and NP patients with moderate-to-severe pruritus. The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority. MEDIA CONTACT:Claire LaCagnina6 Degrees315email@example.com INVESTOR CONTACT:Janhavi MohiteStern Investor Relations, Inc.212-362-1200janhavi.mohite@SternIR.com